ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Summary: Menin Inhibitors in AML - FDA Approval and Highlig…

2024 ASH Annual Meeting Insights Hub

J. Zeidner

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

ASH 2024 Insights: POLARIX 5yr Update - Pola-R-CHP vs. R-CHOP in 1L …

2024 ASH Annual Meeting Insights Hub

G. Salles

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

2024 ASH Annual Meeting Insights Hub

J. Watts

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger